Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats

Annals of Hepatology

Volumn 8, Issue 2, 2009, Pages 134-140

  El Sherbiny, Gamal A ^a   Taye, Ashraf ^b   Abdel Raheem, Ihab T ^c  

^a Beni Suef University   (Egypt)

^b Minia University   (Egypt)

^c Al Azhar University   (Egypt)

Author keywords

Amoxicillin; Clavulanic acid; Hepatotoxicity; Oxidative stress; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLAVULANIC ACID; GLUTATHIONE; MALONALDEHYDE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID PEROXIDATION; LIVER HOMOGENATE; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PREMEDICATION; RAT; TREATMENT DURATION;

EID: 67650519656     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31792-2     Document Type: Article

References (50)

1. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1,100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232(2): 133-138.
2. Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003; 325(1): 31-33. (Pubitemid 36109686)
3. Garcia-López M, Martinez-Blanco M, Martinez-Mir I, Palop V. Amoxicillin-clavulanic acid-related tooth discoloration in children. Pediatrics 2001; 108(3): 819-823.
4. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47(5): 717-720. (Pubitemid 30809053)
5. Jordan T, Gonzalez M, Casado M, Suarez JF. Amoxicillinclavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol 2002; 25(4): 240-243. (Pubitemid 34847188)
6. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129(2): 512-521. (Pubitemid 41096639)
7. Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990; 25(6): 774-780.
8. Poupon RE, Eschwège E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol 1990; 11(1): 16-21. (Pubitemid 20250821)
9. Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A doubleblind controlled study. Eur J Clin Pharmacol 1991; 40(5): 473-476.
10. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16(3): 707-714.
11. Poupon R, Serfaty L. Ursodeoxycholic acid in chronic hepatitis C. Gut 2007; 56(12): 1652-1653.
12. Kotb MA. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: Review of a historical cohort. Dig Dis Sci 2008; 53(12): 3112-3118.
13. Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Nippon Shokakibyo Gakkai Zasshi 1975; 72(6): 690-702.
14. Salen G, Tint GS, Shefer S. Treatment of cholesterol gallstones with litholytic bile acids. Gastroenterol Clin North Am 1991; 20(1): 171-182.
15. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32(6): 1196-1199.
16. Nishio A, Keeffe EB, Ishibashi H, Gershwin EM. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Monit 2000; 6(1): 181-193. (Pubitemid 30158263)
17. Guicciardi ME, Gores GJ. Is ursodeoxycholate an antiapoptotic drug. Hepatology 1998; 28(6): 1721-1723.
18. Lukivskaya O, Lis R, Egorov A, Naruta E, Tauschel HD, Buko VU. The protective effect of ursodeoxycholic acid in alloxaninduced diabetes. Cell Biochem Funct 2004; 22(2): 97-103. (Pubitemid 38316024)
19. Ljubuncic P, Abu-Salach O, Bomzon A. Ursodeoxycholic acid and superoxide anion. World J Gastroenterol 2005; 11(31): 4875-4878.
20. Lukivskaya O, Zavodnik L, Knas M, Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv Med Sci 2006; 51: 54-59.
21. Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, Senturk O, et al. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig Dis Sci 2008; 53(4): 1071-1077.
22. Woodnut G, Berry V. Efficacy of high-dose amoxicillinclavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumonia. Antimicrob Agents Chemother 1999; 43(1): 35-40. (Pubitemid 29069196)
23. De Haan F, Stricker BH. Liver damage associated with the combination drug amoxicillin-clavulanic acid (Augmentin). Ned Tijdschr Geneeskd 1997; 141(26): 1298-1301. (Pubitemid 27294491)
24. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28(1): 56-63.
25. Eaton RH. Plasma alkaline phosphatase assay: interconversion of results by two methods. Clin Chem 1977; 23(11): 2148-2150. (Pubitemid 8220663)
26. Merino RA, Lalive J, Parga GL. Critical analysis of bilirubinemia and diagnostic value of direct bilirubin determination by the Malloy-Evelyn method. Rev Med Chil 1968; 96(12): 794-798.
27. Sedlák J, L' Hanus. Changes of glutathione and protein bound SH-groups concentration in rat adrenals under acute and repeated stress. Endocrinol Exp 1982; 16(2): 103-109. (Pubitemid 12017099)
28. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
29. Warren JS, Yabroff KR, Remick DG, Kunkel SL, Chensue SW, Kunkel RG, Johnson KJ, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 1989; 84(6): 1873-1882. (Pubitemid 20016193)
30. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003; 14(8 Suppl 3): S221-6. (Pubitemid 36903929)
31. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101(12): 2790-2799. (Pubitemid 28294588)
32. Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007; 76: 551-573.
33. Parks DA, Granger DN. Ischemia-reperfusion injury: a radical view. Hepatology 1988; 8(3): 680-682.
34. Li X, Liu Y, Song L, Liu J. Responses of antioxidant systems in the hepatocytes of common carp (Cyprinus carpio L.) to the toxicity of microcystin-LR. Toxicon 2003; 42(1): 85-89. (Pubitemid 37297564)
35. Eberle D, Clarke R, Kaplowitz N. Rapid oxidation in vitro of endogenous and exogenous glutathione in bile of rats. J Biol Chem 1981; 256: 2115-2117. (Pubitemid 11151467)
36. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002; 64(11): 1661-1667.
37. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 1994; 20(6): 1595-1601. (Pubitemid 24359075)
38. Serviddio G, Pereda J, Pallardo FV, Carretero J, Borras C, Cutrin J, Vendemiale G, et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39(3): 711-720. (Pubitemid 38337650)
39. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263(2): 537-542. (Pubitemid 29467230)
40. Geetha A, Parameswari S. Effect of ursodeoxycholic acid on hydrogen peroxide induced lipid peroxidation in sheep liver mitochondria. Indian J Physiol Pharmacol 2002; 46(3): 343-348. (Pubitemid 35050331)
41. Palomero J, Galán AI, Muñoz ME, Tuñón MJ, González-Gallego J, Jiménez R. Effects of aging on the susceptibility to the toxic effects of cyclosporin A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic Biol Med 2001; 30(8): 836-845. (Pubitemid 32289261)
42. Kaur S, Kaur U, Tandon C, Dhawan V, Ganguly NK, Majumdar S. Gastropathy and defense mechanisms in common bile duct ligated portal hypertensive rats. Mol Cell Biochem 2000; 203(1- 2): 79-85. (Pubitemid 30111779)
43. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Amoxicillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs 1981; 22(5): 337-362. (Pubitemid 12213887)
44. Tsuji K, Kubota Y, Yamamoto S, Yanagitani K, Amoh Y, Takaoka M, Ogura M, et al. Increased neutrophil chemotaxis in obstructive jaundice: an in vitro experiment in rats. J Gastroenterol Hepatol 1999; 14(5): 457-463. (Pubitemid 29256181)
45. Tanaka J, Yuda Y, Yamakawa T. Mechanism of superoxide generation system in indomethacin-induced gastric mucosal injury in rats. Biol Pharm Bull 2001; 24: 155-158. (Pubitemid 32175566)
46. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillẽres O, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48(3): 871-877.
47. Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Scand J Gastroenterol Suppl 1994; 204: 40-46. (Pubitemid 24302611)
48. Chretien Y, Poupon R, Gherardt MF, Chazouilleres O, Labbe D, Myara A, Trivin F. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut 1989; 30(8): 1110-1115. (Pubitemid 19202211)
49. Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, Northfield TC. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106(1): 134-142. (Pubitemid 24011874)
50. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6(3): 755-774.